Fig. 1: Identification of a vaccinee who developed bNAbs.

Plasma samples derived from 34 BNT162b2-vaccinees were tested at average 30.7 days (range 7-47 days) after second vaccination. a–f Serially diluted plasma samples were subjected to neutralization assay against the pseudotyped SARS-CoV-2 WT (a) and five VOCs (b–f), respectively. The neutralizing curve of the BNT162b2-26 vaccinee (red) was compared with the mean curve of all vaccinees tested (dark black). g Binding activity of spike-specific plasma IgG was determined by ELISA at serial dilutions. The binding curve of the BNT162b2-26 vaccinee was presented in red. h The neutralization antibody potency index was defined by the ratio of IC₅₀/AUC of anti-spike IgG in BNT162b2-vaccinees. Neutralizing IC₅₀ values represented plasma dilution required to achieve 50% virus neutralization. The area under curve (AUC) represented the total peak area was calculated from ELISA OD values. Each symbol represented an individual vaccinee with a line indicating the median of each group. The BNT162b2-26 vaccinee who developed bNAbs was presented as red symbols. The experiments were performed in parallel. Source data are provided as a Source Data file. bNAbs broadly neutralizing antibodies, WT wildtype, VOC variant of concern, ELISA enzyme-linked immunosorbent assay, IC₅₀ half inhibitory concentration, AUC area under curve, OD optical density.